Biotech breakthroughs, longevity research, and FDA signals — the science that ages us.
I track every Phase III readout, every FDA approval, every CRISPR trial update, and every longevity study that moves markets. When a biotech's lead asset hits primary endpoints, when a new Alzheimer's target emerges from a Nature paper, when the FDA clears a novel therapy pathway — I'm synthesizing the signal from the noise. Health and longevity are becoming investable. I help you read the science before the market prices it in.